Arbutus Biopharma Corporation Common Stock (ABUS) Technical Analysis
$4.85
Market is closed - opens 7 PM, 28 Sep 2026
Insights
- Arbutus Biopharma Corporation is currently in a neutral trading position according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Arbutus Biopharma Corporation stock suggests that it is a good time to buy
- Based on analysis of the Moving Averages technical indicator, Arbutus Biopharma Corporation stock is Range bound.
- Based on analysis of the Pivot Points, the current market trend for Arbutus Biopharma Corporation stock suggests that it is a good time to sell or bad time to initiate a fresh position
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 42.58 | Neutral |
Stochastic | 18.43, 11.0 | Buy |
Ultimate Oscillator | 37.9 | Neutral |
Stochastic Relative Strength Index | 5.27, 2.99 | Buy |
Moving Average Convergence Divergence | 0.02, 0.06 | Sell |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 5.02 | Sell |
20 | 5.07 | Buy |
50 | 4.81 | Buy |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 4.99 | Sell |
20 | 5.0 | Buy |
50 | 4.88 | Buy |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 5.0 | Neutral |
20 | 5.05 | Neutral |
50 | 5.0 | Neutral |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 4.93 | Sell |
20 | 5.05 | Sell |
50 | 5.08 | Buy |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 4.88 | Sell |
20 | 4.97 | Sell |
50 | 5.13 | Buy |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 5.15 |
Resistance L2 | 5.08 |
Resistance L1 | 4.97 |
Pivot Point | 4.9 |
Support L1 | 4.79 |
Support L2 | 4.72 |
Support L3 | 4.61 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.